In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Follow-on Biologics Workshop

Follow-on Biologics Workshop

Monday, December 12, 2005 - Wednesday, December 14, 2005

New York Marriott at the Brooklyn Bridge

Presented By

Presented by the New York Academy of Sciences, the U.S. Food and Drug Administration, and the National Institute of Standards and Technology


The goal of this meeting is to address the scientific issues associated with the characterization and demonstration of similarity of protein pharmaceutical products. This event will provide an overview of currently available analytical methodologies and technologies as well as perspectives on future technology. The focus will be on the use of analytical techniques to characterize follow-on biologics and on the role of the fermentation and purification processes in determining product quality attributes. Also addressed will be challenges to characterizing and comparing proteins in the absence of reference standards for the active pharmaceutical ingredient.

Organizing committee:

  • Kurt Brorson, CDER, FDA
  • David Bunk, NIST
  • Andrew Chang, CBER, FDA
  • Barry Cherney, CDER, FDA
  • Kathleen A. Clouse, CDER, FDA
  • Blair Fraser, CDER, FDA
  • Travis Gallagher, NIST
  • Marcia Holden, NIST
  • Christopher Joneckis, CBER, FDA
  • Curtis Meuse, NIST
  • Stephen Moore, CDER, FDA
  • Amy Rosenberg, CDER, FDA
  • Emily Shacter, CDER, FDA
  • Marjorie Shapiro, CDER, FDA
  • Victoria R. Sutton, CDER, FDA